Overview

Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery

Status:
Active, not recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative Induction therapy with 12 weeks of panitumumab with mFOLFOX-6 to evaluate the efficacy in terms of pathologic complete response (pCR)

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Espanol Multidisciplinario del Cancer Digestivo

Collaborators:

Amgen
Pivotal S.L.

Treatments:

Antibodies, Monoclonal
Fluorouracil
Leucovorin
Oxaliplatin
Panitumumab